New lupus drug enters early human testing
NCT ID NCT06625671
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new drug called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. About 148 participants will receive either DB-2304 or a placebo. This is a first step to see if the drug is safe enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DB-2304
What this could lead to
If it works, this could point toward a new treatment option for lupus that helps control the disease.
What could go wrong
This is a very early, small trial focused on safety and dosing. It is not designed to prove effectiveness, and many early-stage drugs fail to show benefit in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site AUS01-0
COMPLETEDMelbourne, Victoria, 3004, Australia
-
US02-0
RECRUITINGSan Antonio, Texas, 78215, United States
-
US03-0
RECRUITINGClearwater, Florida, 33765, United States
-
US04-0
RECRUITINGIrving, Texas, 75061, United States
-
US05-0
RECRUITINGOrlando, Florida, 32808, United States
-
US06-0
RECRUITINGLa Palma, California, 90623, United States
-
US08-0
NOT_YET_RECRUITINGSyracuse, New York, 13210, United States